02575.HK
Xuanzhubio-b
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
HKD 8.60
+0.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 116.9M | 56.1M | 32.6M | 32.0K | — |
| Cost of Revenue | 76.7M | 34.4M | 45.2M | 35.6M | 30.2M |
| Gross Profit | 40.2M | 21.8M | (12.6M) | (35.5M) | (30.2M) |
| Operating Expenses | |||||
| R&D Expense | 76.2M | 120.3M | 180.9M | 238.7M | 444.9M |
| SG&A Expense | 177.1M | 146.3M | 413.0M | 95.6M | 100.4M |
| General & Admin Expense | 81.4M | — | — | — | — |
| Selling & Marketing Expense | 95.7M | — | — | — | — |
| Other Expenses | — | 8.3M | 4.7M | 4.8M | 4.7M |
| Total Operating Expenses | 253.3M | 274.9M | 598.7M | 339.2M | 550.1M |
| Cost and Expenses | 330.0M | 309.3M | 643.9M | 374.7M | 580.2M |
| Operating Income (EBIT) | (213.0M) | (253.1M) | (611.3M) | (374.7M) | (580.2M) |
| Non-Operating | |||||
| Interest Income | — | 7.4M | 7.2M | 15.9M | 27.6M |
| Interest Expense | — | 134.5K | 329.6K | 1.3M | 1.8M |
| Net Interest Income | 3.5M | 7.2M | 6.9M | 14.6M | 25.9M |
| Other Non-Op Income/Expense | (21.7M) | (13.1M) | 8.0M | 42.6M | (15.5M) |
| Non-Operating Income (excl Interest) | 8.1M | — | (8.3M) | (43.9M) | 13.7M |
| EBT (Pre-Tax Income) | (234.8M) | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Income Tax Expense | 6.9K | 6.5K | 6.5K | 6.6K | 5.8K |
| Bottom Line | |||||
| Net Income | (234.8M) | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Earnings from Cont. Ops | (234.8M) | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (234.8M) | (266.3M) | (603.3M) | (332.1M) | (595.7M) |
| Per Share | |||||
| Basic EPS | (HK$0.48) | (HK$0.51) | (HK$1.16) | (HK$0.64) | (HK$1.15) |
| Diluted EPS | (HK$0.48) | (HK$0.51) | (HK$1.16) | (HK$0.64) | (HK$1.15) |
| Revenue Per Share | HK$0.23 | HK$0.11 | HK$0.06 | HK$0.00 | HK$0.00 |
| Shares | |||||
| Basic Shares Outstanding | 517.9M | 517.9M | 517.9M | 517.9M | 517.9M |
| Diluted Shares Outstanding | 517.9M | 517.9M | 517.9M | 517.9M | 517.9M |
| Profitability Metrics | |||||
| EBITDA | (185.7M) | (220.5M) | (566.4M) | (295.3M) | (563.8M) |
| D&A | 35.4M | 32.6M | 36.6M | 35.5M | 30.2M |
| EBIT | (221.1M) | (253.1M) | (603.0M) | (330.8M) | (593.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026